Actively Recruiting
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2023-05-23
50
Participants Needed
1
Research Sites
291 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
CONDITIONS
Official Title
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed Informed Consent Form
- Age 18 years or older at enrollment
- At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy
- Relapsed or refractory to front-line anti-lymphoma therapy as defined by specific tumor response or relapse criteria
- Planned treatment with obinutuzumab in combination with lenalidomide
You will not qualify if you...
- Currently participating or planning to participate in any interventional clinical trial
- Any other reason judged by the investigator that makes the patient unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
Tianjin, China, 300020
Actively Recruiting
Research Team
S
shuhua Yi, Dr
CONTACT
L
Lugui Qiu, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here